Apollo | Sponsored by Alynlam Pharmaceuticals, Inc.

Apollo Clinical Trial
header image

TTR amyloidosis (FAP) is an inherited genetic disease passed down through families, impacting one generation
after the next.

Patient stories

FAP and your family

Today, TTR amyloidosis (FAP) affects approximately 10,000 people worldwide. Symptoms can begin over a wide range of ages, any time between ages 20 and 70, with symptoms progressing for an average of 10 years.

That is how TTR amyloidosis (FAP) can have an ongoing impact on both patients and their families. The disease is inherited from one affected parent. People with no family history of TTR amyloidosis (FAP) can develop the disease, but it’s usually passed down within families, impacting one generation after the next.

Has your family been affected? Learn more about Alnylam Assist >

Cause and symptoms

TTR amyloidosis (FAP) is caused by a mutation in the transthyretin (TTR) gene. This mutation causes a protein called amyloid to build up in organs and tissues, leading to a condition called familial amyloidotic polyneuropathy (FAP).

Signs and symptoms include:

  • Numbness, tingling, and loss of feeling in the feet and hands
  • Muscle wasting, stiffness, and weakness
  • Trouble moving, walking, or performing fine motor skills
  • Nausea, vomiting, constipation, and diarrhea
  • Serious eye, heart, and kidney problems
  • Erectile dysfunction